NCT07745725尚未招募2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of TollB-001 Tablets in Patients With Systemic Sclerosis
Toll Biotech Co. Ltd. (Beijing)2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2026年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Rodnan Skin Score (mRSS)
研究概览
简要总结
The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).
详细描述
Study Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of TollB-001 in Adult Patients with Systemic Sclerosis (SSc) Study Design: This is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of TollB-001 in adult patients with systemic sclerosis (SSc).
Sample Size and Target Population: A total of 36 patients with SSc are planned for enrollment. Eligible patients must have a disease duration of ≤ 60 months from the first onset of non-Raynaud's phenomenon and a modified Rodnan Skin Score (mRSS) between 10 and 40 (inclusive) at the screening visit.
Study Phases: The study consists of three sequential phases:
Screening Period: Up to 28 days
Treatment Period: 90 days, comprising:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 70 years (inclusive), male or female.
- •Diagnosis of systemic sclerosis (SSc) according to the 2013 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria.
- •Meeting the classification criteria for diffuse cutaneous systemic sclerosis (dcSSc) as defined in the 2022 Chinese Guideline for the Diagnosis and Treatment of Systemic Sclerosis.
- •Evidence of active disease at screenin.
- •Female participants of childbearing potential and male participants must use effective contraception during the study and for 3 months after the last dose of study drug. Male participants whose partners are females of reproductive potential must agree to use effective contraception and refrain from donating sperm during the study and for 3 months after the last dose. Female participants of childbearing potential must have a negative pregnancy test.
- •Able to swallow all study medications.
- •Willing and able to comply with the study protocol (e.g., able to understand and complete questionnaires, adhere to visit schedules, and take study medication) and provide signed informed consent.
排除标准
- •Known hypersensitivity to any active ingredient or excipient of the study drug, or to drugs of the same class.
- •History of scleroderma renal crisis within 6 months prior to randomization.
- •Clinically significant chronic intermittent bleeding within 4 weeks prior to screening (e.g., active gastric antral vascular ectasia, active peptic ulcer, or duodenal ulcer), or participants at risk of bleeding.
- •Any active malignancy or history of malignancy.
- •Presence of severe, uncontrolled diseases.
- •Major surgery within 8 weeks prior to randomization, or expected to undergo major surgery after enrollment.
- •Drug or alcohol abuse or dependence at screening, or a history of drug or alcohol abuse or dependence within 6 months prior to randomization.
- •Participation in another clinical trial within 3 months prior to the date of informed consent, or planning to participate in another clinical trial during the study period.
- •Participants who, in the investigator's judgment, are unsuitable for participation in this clinical trial.
结局指标
主要结局
Rodnan Skin Score (mRSS)
时间窗: up to 12 weeks
次要结局
- Incidence of Serious Adverse Events(up to 12 weeks)
- Incidence of Serious Adverse Reactions(up to 12 weeks)
- Incidence and Severity of Adverse Reactions(up to 12 weeks)
- Composite Response Index in Systemic Sclerosis (CRISS)(up to 12 weeks)
- Forced Vital Capacity (FVC)(up to 12 weeks)
- Health Assessment Questionnaire- Disability Index (HAQ-DI)(up to 12 weeks)
- Patient Global Assessment (PtGA)(up to 12 weeks)
- Incidence and Severity of Adverse Events(up to 12 weeks)
- The four major vital signs, including body temperature, pulse (heart rate), respiration, and blood pressure.(up to 12 weeks)
- The 12-lead electrocardiogram (ECG) includes parameters such as heart rate, RR interval, PR interval, QT interval, QRS interval, and the corrected QT interval (QTcf, where QTcf = QT / RR^0.33).(up to 12 weeks)
- Routine blood test includes parameter such as white blood cell, lymphocyte count and percentage, neutrophil count and percentage, monocyte count and percentage, eosinophil count, basophil count, , red blood cell, hemoglobin, hematocrit, platelet count.(up to 12 weeks)
- Blood biochemical parameters such as: aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, indirect bilirubin, total protein, albumin, alkaline phosphatase, gamma-glutamyl transferase (GGT) and urea, etc.(up to 12 weeks)
- Coagulation function parameters suc as the International Normalized Ratio (INR), activated partial thromboplastin time (APTT), prothrombin time (PT), and fibrinogen.(up to 12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic AtrophyGeographic Atrophy Due to Age-Related Macular DegenerationNCT07668804Theratocular Biotek Co.31
尚未招募
2 期
QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis SuppurativaNCT07417917Qilu Pharmaceutical Co., Ltd.102
招募中
1 期
A Study to Evaluate ALN-2232 in Participants With ObesityObesityNCT07463846Alnylam Pharmaceuticals156
已完成
1 期
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive EpisodeMajor Depressive Disorder (MDD)SchizophreniaBipolar DisorderNCT07549581Otsuka Pharmaceutical Development & Commercialization, Inc.43
招募中
1 期
A First-in-human Trial of GRT7041 in Healthy ParticipantsNCT07289776Grünenthal GmbH70